Amgen Inc. (VIE:AMGN)
Austria · Delayed Price · Currency is EUR | Market Cap | 162.47B +4.3% |
| Revenue (ttm) | 31.30B +10.0% |
| Net Income | 6.57B +88.5% |
| EPS | 12.12 +88.2% |
| Shares Out | n/a |
| PE Ratio | 24.74 |
| Forward PE | 15.52 |
| Dividend | 8.36 (2.76%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | n/a |
| Average Volume | 116 |
| Open | 305.90 |
| Previous Close | 304.60 |
| Day's Range | 303.40 - 305.90 |
| 52-Week Range | 230.50 - 332.55 |
| Beta | n/a |
| RSI | 41.22 |
| Earnings Date | Apr 30, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction in Proptosis; Greater Than 3 mm THOUSA...
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab's inve...
FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths
The FDA said it has identified 76 cases of drug-induced liver injuries with reasonable evidence of being causally linked to Tavneos.
US FDA warns of liver injury cases tied to Amgen's rare disease drug
The U.S. Food and Drug Administration on Monday said it had identified cases of liver injury in patients taking Amgen's drug for a group of rare autoimmune diseases and urged healthcare providers to...
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
GSK and Amgen to add medicines to TrumpRx, Fox Business reports
GSK and Amgen will add their medicines to TrumpRX, the prescription drug website launched by President Donald Trump's administration, Fox Business reported on Friday.
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m.
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026.
AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
THOUSAND OAKS, Calif., Feb. 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m.
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m.
Prices, pipelines and patent cliffs: Inside pharma's big reset
Pharma earnings weren't the main focus for drugmakers this quarter. "2025 was about understanding kind of the rules of the future of the game," McKinsey Senior Partner Greg Graves told CNBC.
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026
New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (Nasdaq: CCXIU) (the “Company”) announced today that, commencing February 9, 2026, holders of the units sold in the Company's ...
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1.
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in th...
Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost
The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue and lower net unrealized losses on equity investments.
Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% increase in drug sales and a lower tax rate.
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.